Globally, cervical cancer is the third most common cancer in women ([@bib15]). Pelvic lymph node metastasis (PLNM) is a critical factor for determining the individualised treatment and prognosis of cervical cancer, particularly in early-stage cervical cancer (CC, I--IIst) ([@bib11]). The primary treatment for CC, I--IIst is either surgery or chemoradiotherapy. For patients with low risk of PLNM, surgical treatment (radical hysterectomy/conisation/trachelectomy plus lymph node (LN) dissection) can offer hope of fertility or function preservation for young patients and may avoid the long-term complications of chemoradiotherapy ([@bib19]; [@bib33]; [@bib3]). For patients with high risk of PLNM, primary chemoradiotherapy should be recommended. However, because it is difficult to clinically detect LN metastasis efficiently and reliably, some patients receive suboptimal treatment (first unnecessary surgery with adjuvant chemoradiotherapy) ([@bib34]). Combining surgery and chemoradiotherapy leads to a higher morbidity, such as urological complications and lymph oedema ([@bib20]). Therefore, before the first treatment, stratification of CC, I--IIst patients based on PLNM is crucial to planning the optimal individualised treatment.

Imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are routinely used in preoperative examinations of PLNM. Nonetheless, these imaging modalities have relatively low sensitivity ([@bib5]; [@bib6]) for assessing PLNM in CC, I--IIst. Recently, laparoscopic lymphadenectomy was recommended before fertility-preserving surgery ([@bib39]). However, lymphadenectomy is both invasive and associated with intraoperative and postoperative morbidity ([@bib37]). Sentinel LN (SLN) biopsy is considered to be feasible for detecting the status of LN in early-stage cervical cancer ([@bib32]). SLN biopsy can not only enhance the sensitivity and specificity of the diagnosis of PLNM but also reduce the extension of pelvic lymphadenectomy. Although it is less invasive than open and laparoscopic surgery, SLN biopsy still requires a general anaesthesia. At the present time, there are no known non-invasive and highly accurate detection methods that may be used to assess PLNM in CC, I--IIst before the first treatment. Therefore, an urgent need to identify biomarkers for PLNM in CC, I--IIst exists.

Previous studies for identifying PLNM-associated biomarkers in cervical cancer focused mainly on the transcriptomic ([@bib12]) and genomic levels ([@bib18]; [@bib13]). However, alterations at the protein level can reflect cellular changes more accurately. Advances in bioinformatics and high-throughput technologies have provided powerful tools for unravelling the proteomic profile during PLNM progression. A recent study investigated sera from CC, I--IIst patients using surface-enhanced laser desorption/ionisation-time-of-flight mass spectrometry (SELDI-TOF-MS), and found that a model based on three differentially expressed peaks could determine LN status ([@bib38]). However, this study failed to identify the proteins represented by the three differentially expressed peaks. In contrast, our study was performed with primary CC, I--IIst tissue. Analysis of CC, I--IIst tissue has several potential advantages: first, there is an inherent link between the differential proteins and the tumour itself; second, we can take into account the contributions of the tumour microenvironment by testing protein expression in tissue, because the tumour microenvironment has a vital role in cancer metastasis ([@bib21]), and finally, primary cervical cancer tissue can be easily acquired by transvaginal biopsy before surgery. To our knowledge, there are no reports on the use of tissue-based proteomics to identify biomarkers associated with PLNM of CC, I--IIst.

The aim of this study was to identify biomarkers for PLNM of CC, I--IIst. We applied two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption/ionisation-time-of-flight mass spectrometry (MALDI-TOF/TOF MS) to identify differential proteins between primary CC, I--IIst tissue with and without PLNM. Three differential proteins were further validated on an independent tissue cohort to evaluate their reliability in predicting PLNM of CC, I--IIst.

Materials and methods
=====================

Tissue sample collection
------------------------

The study was approved by the Ethical Committee of the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Informed consent was obtained from each patient. Eighteen patients with early-stage cervical squamous cell cancer who underwent radical hysterectomy and pelvic lymphadenectomy at the First Affiliated Hospital of Sun Yat-sen University from January 2011 to September 2012 were recruited. None of these patients received preoperative radiation or chemotherapy, and none was documented as having other diseases per systematic examination before surgery. Based on the postoperative pathological examinations of pelvic LN (PLN), the CC, I--IIst cases were assigned into PLNM group (*n*=8) and non-PLNM (NPLNM) group (*n*=10). The clinicopathological characteristics of the tumour samples are shown in [Table 1](#tbl1){ref-type="table"}. There was no difference between the two groups in clinicopathological factors. To obtain tumour tissue, while on ice, each tissue sample was assessed and dissected by an experienced pathologist immediately after tumour resection. The pathologist then confirmed that each dissected tumour tissue block was composed of at least 80% tumour cells by frozen section examination. Dissected tissue samples were snap-frozen in liquid nitrogen with the shortest possible delay and were then stored at −80 °C until use.

For immunohistochemistry (IHC) validation, an independent tissue cohort with 105 early-stage cervical squamous cell cancer samples (22 PLNM, 83 NPLNM) was used ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). This cohort of paraffin-embedded tissue material was collected from the archives of the pathology department at the First Affiliated Hospital of Sun Yat-sen University. Surgeries were performed between 2003 and 2007. None of the patients received radiotherapy and/or chemotherapy before surgery. All specimens were handled according to legal and ethical standards.

Protein sample preparation
--------------------------

Tissue (∼100 mg) was mechanically homogenised in lysis buffer (2 M thiourea, 7 M urea, 30 m[M]{.smallcaps} Tris, 4% *w/v* CHAPS) on ice. These homogenates were sonicated intermittently and then separated by centrifugation at 20, 000 r.p.m. for 40 min at 4°C. The supernatant was collected. To purify the protein extract and to quantify the final protein concentration, a 2-D clean-up kit (Amersham Biosciences, Buckinghamshire, UK) and a 2-D Quant Kit (GE Healthcare, London, UK) were used sequentially according to the manufacturers\' instructions. Equal amounts of proteins extracted from the same group were pooled for DIGE analysis.

Protein sample labelling with CyDye
-----------------------------------

CyDye DIGE fluors (Cy2, Cy3, and Cy5) were used to label the protein extracts following the manufacturer\'s protocol (GE Healthcare). The internal standard pool was generated by combining equal amounts of extracts from all samples, labelled with Cy2. Protein extracts from the PLNM and NPLNM groups were labelled with Cy3 and Cy5, respectively. The labelling reaction was performed on ice for 30 min in darkness, and was then quenched with 10 m[M]{.smallcaps} lysine for 10 min on ice under dark conditions. The labelled samples were then mixed and prepared for the following steps.

Two-dimensional electrophoresis
-------------------------------

After rehydration, the labelled protein mixture for each gel was applied to an immobilised pH gradient (IPG) strip (24 cm, pH 3-10 NL; GE Healthcare). Isoelectric focusing (IEF) was performed following the manufacturer\'s instructions with an Ettan IPGphor II System (GE Healthcare). After IEF, the proteins were reduced with equilibration buffer containing 2% *w/v* dithiothreitol (DTT) for 15 min. The proteins were then alkylated with equilibration buffer containing 2.5% *w/v* iodoacetamide for 15 min. The second dimension of electrophoresis was conducted using an Ettan DALT-VI system (GE Healthcare).

Gel image acquisition and analysis
----------------------------------

The Typhoon 9400 imager (GE Healthcare) was used to visualise labelled proteins at excitation/emission wavelengths of 488/520 nm (cy2), 532/580 nm (cy3), and 633/670 nm (cy5). DeCyder software (V6.0, GE Healthcare) was used to analyse the 2-D DIGE gel images. Protein spots with significant differences in abundance (increased or decreased more than \>1.5-fold) were selected for further analysis.

Spot picking and enzymatic digestion
------------------------------------

Using an Ettan Spot Handling Workstation (GE Healthcare), the selected protein spots were automatically picked up and treated. The protein spots were washed with 25 m[M]{.smallcaps} NH~4~HCO~3~ and 50% acetonitrile and were then digested with 8 ng *μ*l^−1^ trypsin solution (mass spectrometry grade; Promega, Madison, WI, USA) in 25 m[M]{.smallcaps} NH~4~HCO~3~ for 16 h at 37°C. After digestion, the tryptic peptides were extracted with 60% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid (TFA). Finally, the tryptic peptides were dissolved in 4 mg ml^−1^ 4-hydroxy-alpha-cyanocinnamic acid matrix in 70% (v/v) acetonitrile and 0.1% (v/v) TFA and were spotted on the target plate.

MALDI-TOF/TOF MS analysis
-------------------------

In positive ion reflector mode, an Ultraflex III MALDI-TOF/TOF MS (Bruker, Karlsruhe, Baden- Württemberg, Germany) was used to perform MS analysis. Four of the most intense ion signals were automatically chosen as precursors for MS/MS acquisition, excluding the matrix ion signals and trypsin autolysis peaks. MASCOT Version 2.2 (Matrix Science, London, UK) and Biotools software (Version 3.2, Bruker) were used to search the MS/MS spectra combined peptide mass fingerprint in the NCBInr database. The following search criteria were used: Homo sapiens, trypsin cleavage, oxidation of methionines allowed as variable modification, one missed cleavage allowed, carbamidomethylation as fias modification, peptide mass tolerance at 75 ppm, and fragment tolerance at 0.5 Da. A successfully identified protein had the following parameters: ion score confidence interval (CI%) for PMF and MS/MS data ⩾95%, distinct sequences identified in MS/MS analysis ⩾2 and peptide count (hit) ⩾4.

Differential proteins categorisation and network modelling
----------------------------------------------------------

The differential proteins were assorted using the protein analysis through evolutionary relationships (PANTHER) system (<http://www.pantherdb.org>). The PANTHER ontology is a highly controlled vocabulary categorised according to biological process, protein class, and molecular function.

To establish an interaction map among the differential proteins, we used Pathway Studio 5.0 software (Ariadne Genomics, Rockville, MD, USA), a text-mining tool that can construct protein interaction networks and pathways. It includes protein--protein interactions, pathway components, proteins and their cellular processes, and functional classes. In this study, we selected the shortest path analysis.

Western blotting
----------------

Western blotting was performed on the same set of samples used in the DIGE analysis. Briefly, 50 *μ*g pooled protein extracts of each group were fractionated by 10% SDS-PAGE and transferred to a PVDF membrane as previously described ([@bib22]). The signal was detected with an enhanced chemiluminescence (ECL) plus kit (Milipore, Bedford, MA, USA). Anti-manganese superoxide dismutase (anti-MnSOD) (1 : 2000), anti-heat shock protein B1 (anti-HspB1) (1 : 1000), anti-fatty acid binding protein 5 (anti-FABP5) (1 : 1000), and anti-glycerol-3-phosphate dehydrogenase (anti-GAPDH) (1 : 1000) were used. All of these antibodies were rabbit polyclonal antibodies and were purchased from Abcam, Inc. (Cambridge, MA, USA).

Immunohistochemistry
--------------------

Immunohistochemistry staining was performed using various primary antibodies including anti-MnSOD (1 : 600), anti-HspB1 (1 : 1200), and anti-FABP5 (1 : 600) as previously described ([@bib31]). These antibodies are the same as those used in western blotting. In negative controls, primary antibodies were omitted. Two experienced pathologists assessed the immunostaining in a blinded fashion as described previously ([@bib4]). The results were scored by adding the staining intensity (0=no, 1=weak, 2=moderate, 3=strong staining) and the staining area (0=no, 1=\<30%, 2=between 30% and 60%, 3=between 60 and 100% stained cells). For statistical analysis, the immunostaining scores (ranging from 0 to 6) were evaluated and a cut-off was determined. The samples were divided accordingly into low- and high-staining groups. For HspB1, a staining score of 4 was defined as the cutoff. For MnSOD and FABP5, a staining score of 3 was defined as the cutoff.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA) and MedCalc statistical software (MedCalc Software, Mariakerke, Belgium). The relationships between the FABP5, HspB1, and MnSOD expression levels and clinicopathological factors were evaluated using the Pearson *χ*^2^ test or Fisher\'s exact test. Logistic regression analyses (univariate and stepwise multivariate) were used to determine variable predictability of PLNM. Receiver operating characteristic (ROC) analysis was used to test the discriminatory power of measured markers. The Kaplan--Meier method was used to construct relapse-free probability curves and overall survival curves, and the curves were compared by the log-rank test. *P* \<0.05 was considered to be statistically significant.

Results
=======

Identification of differential proteins in primary early-stage cervical cancer with and without PLNM by proteomic analysis
--------------------------------------------------------------------------------------------------------------------------

Protein extracts from tissue homogenates were subjected to DIGE analysis. [Figure 1](#fig1){ref-type="fig"} shows a typical DIGE gel image. After visual review, 52 differential protein spots with at least a 1.5-fold discrepancy between the two groups were selected for MALDI-TOF/TOF MS analysis. In total, 41 differentially expressed proteins (26 upregulated and 15 downregulated) were successfully identified ([Table 2](#tbl2){ref-type="table"}). Some proteins appeared as multiple spots in DIGE, likely due to their isoforms and/or modifications.

Differential proteins categorisation and network modelling
----------------------------------------------------------

The differential proteins were classified according to biological processes, molecular functions, and protein classes using the PANTHER system ([Figure 4](#fig4){ref-type="fig"}). The proteins were classified into 23 groups based on protein classes, including signalling molecules (14%), calcium-binding proteins (8%), cell adhesion molecules (6%), oxidoreductases (4%), and so on. Most of the proteins participated in the metabolic (15%), cellular (14%), and cell communication processes (12%). The proteins were also involved in other biological processes, such as the immune responses, cell adhesion, the generation of energy, apoptosis and cellular component organisation. Regarding molecular function, the proteins were divided into five categories: (a) catalytic activity (34%), (b) binding (30%), (c) structural molecule activity (21%), (d) receptor activity (6%), and (e) motor activity (3%).

To explore the associations between differentially expressed proteins, we constructed a protein network with Pathway Studio 5.0 software. Complex interactions between mitochondrial, nuclear, cytoplasmic, and extracellular proteins were present in the prediction network ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Further research is needed to explore the role of these proteins and their interaction pathways in the pathogenesis of PLNM in CC, I--IIst.

Validation of differential proteins by western blotting
-------------------------------------------------------

To further confirm the proteomic results, western blotting was performed to examine the expression levels of FABP5, HspB1, and MnSOD in the same pooled protein extracts used in the DIGE analysis. The expression levels of the three proteins were higher in the PLNM group than in the NPLNM group ([Figure 2B](#fig2){ref-type="fig"}). This validation result was consistent with the DIGE analysis.

Validation of differential proteins by IHC
------------------------------------------

Immunohistochemical staining was performed to examine the expression levels of FABP5, HspB1, and MnSOD in an independent tissue cohort of primary CC, I--IIst. Semi-quantitative analysis showed that the PLNM group had significantly higher expression of FABP5, HspB1, and MnSOD than the NPLNM group ([Table 3](#tbl3){ref-type="table"}, [Figure 2A](#fig2){ref-type="fig"}).

Next, the correlation of FABP5, HspB1, and MnSOD with clinicopathological factors was analysed ([Table 3](#tbl3){ref-type="table"}). HspB1 was significantly correlated with PLNM (*P*\<0.001). MnSOD was significantly correlated with PLNM (*P*=0.006), lymphovascular space invasion (LVSI) (*P*=0.01), and stromal invasion (*P*=0.002). FABP5 was significantly correlated with PLNM (*P*\<0.001) and LVSI (*P*=0.001). No significant correlations were identified between the expression of the three proteins and other clinicopathological characteristics, including age, tumour size, tumour differentiation, International Federation of Gynaecology and Obstetrics (FIGO) stage, parametrial invasion, and vaginal invasion.

Correlations of FABP5, HspB1, and MnSOD expression with PLNM
------------------------------------------------------------

Univariate logistic regression analysis revealed that tumour size (*P*=0.003), LVSI (*P*\<0.001), stromal invasion (*P*=0.006), MnSOD (*P*=0.011), HspB1 (*P*=0.001), and FABP5 (*P*\<0.001) were significant predictors of PLNM ([Table 4](#tbl4){ref-type="table"}). Stepwise multivariate logistic regression analysis indicated that LVSI (*P*=0.001), HspB1 (*P*=0.013), and FABP5 (*P*=0.018) were independent predictors of PLNM in patients with CC, I--IIst ([Table 4](#tbl4){ref-type="table"}).

To assess the discriminatory power for the three proteins to predicting PLNM in CC, I--IIst, ROC curves were constructed ([Figure 2C](#fig2){ref-type="fig"}). The three proteins were used as covariates to create a logistic regression model with PLNM as the dependent variable. As a result, we could further evaluate the feasibility of the combination of FABP5, HspB1, and MnSOD to predicting PLNM. The area under the ROC curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for FABP5, HspB1, MnSOD, and the combination of the three proteins are shown in [Table 5](#tbl5){ref-type="table"}. The cut-points (by maximising the Youden index) of FABP5, HspB1, MnSOD, and the combination of the three proteins were 3, 5, 3, and 0.2448 (predicted probability from the logistic regression model of combining the three proteins), respectively. When all three proteins were considered, the discriminatory power was strong (AUC=0.929).

Correlations of FABP5, HspB1, and MnSOD expression with postoperative relapse and survival
------------------------------------------------------------------------------------------

At the end of the study, 34 patients (32.38%) experienced disease recurrence, 31 patients (29.53%) had died of CC, I--IIst, and 74 patients (70.48%) were still alive. The relapse-free probability curves indicated that the relapse rate increased significantly with upregulation of FABP5, HspB1, and MnSOD ([Figure 3](#fig3){ref-type="fig"}). The survival curves indicated that the overall survival rate decreased significantly with upregulation of FABP5, HspB1, and MnSOD ([Figure 3](#fig3){ref-type="fig"}).

Discussion
==========

PLNM is an important prognostic factor in CC, I--IIst, and PLN status is crucial to decision-making about personalised treatment of CC, I--IIst. Currently, it is difficult to diagnose PLNM accurately and efficiently in usual assessment methods used for CC, I--IIst before first treatment. Therefore, reliable biomarkers for clinical diagnosis and better insights into the pathogenesis of PLNM in CC, I--IIst are needed. Our results suggest that FABP5, HspB1, and MnSOD may predict PLNM in CC, I--IIst patients and may also provide information useful to help further elucidate the molecular mechanisms underlying PLNM in CC, I--IIst.

In this study, first, we identified 41 differential proteins between primary early-stage cervical squamous cell cancer tissue with and without PLNM using DIGE-based proteomics. These proteins participate in processes of malignancy progression and metastasis, such as oxidative stress, energy metabolism, cytoskeleton reorganisation, and signal transduction. Second, three differential proteins (FABP5, HspB1, and MnSOD) were validated by western blotting and IHC, indicating that the proteins identified by the proteomic approach were actually differentially expressed proteins. Finally, correlations of the expression levels of the three proteins with clinicopathological factors and clinical outcomes were evaluated in an independent tissue cohort. Our data indicated that FABP5, HspB1, and MnSOD were significantly correlated with PLNM and poor prognosis.

FABP5 is a member of the fatty acid binding protein family with functions in fatty acid uptake, metabolism, and transportation. FABP5 is highly expressed in several types of tumours, such as prostate ([@bib1]), oral ([@bib8]), and hepatocellular carcinomas ([@bib9]). In addition, accumulative studies have shown that upregulation of FABP5 is correlated with tumour metastasis ([@bib8]; [@bib16]). Previous studies reported that overexpression of FABP5 induces metastasis by upregulating vascular endothelial growth factor (VEGF) ([@bib17]) and matrix metalloproteinase 9 (MMP-9) ([@bib8]), which has important roles in the metastatic progression. To our knowledge, there are currently no published reports on the expression of FABP5 in cervical cancer. This study, for the first time, showed that FABP5 was higher expressed in PLNM CC, I--IIst tissue than NPLNM CC, I--IIst tissue and that its upregulation was significantly correlated with PLNM (*P*\<0.001) and poor prognosis (*P*\<0.001). Moreover, the results showed that FABP5 was an independent predictor (*P*=0.018) for CC, I--IIst patients with PLNM in multivariate analysis. Thus, FABP5 may be a biomarker for predicting PLNM of CC, I--IIst. It seems that FABP5 upregulation has a role in the development of PLNM.

HspB1 acts as a molecular chaperone whose main function is to prevent the aggregation of misfolded proteins and to restore denatured proteins. Its functions can be triggered by different types of stress such as inflammation, oxidative stress, and malignant transformation ([@bib7]). HspB1 is overexpressed in several types of malignancies ([@bib14]; [@bib40]) and has been correlated with poor prognosis ([@bib40]). Moreover, it has been reported that upregulation of HspB1 is associated with tumour metastasis ([@bib26]). In cervical cancer, the correlation of HspB1 overexpression with carcinogenesis has been shown ([@bib29]; [@bib24]), but has not yet been associated with PLNM. Our study revealed a significant association of HspB1 expression with PLNM (*P*\<0.001) and that HspB1 was an independent predictor of PLNM in multivariate analysis (*P*=0.013). Thus, our data suggest that HspB1 may be a biomarker of PLNM for CC, I--IIst and that upregulation of HspB1 may be involved in the development of PLNM in CC, I--IIst. Additionally, our data showed that patients with HspB1 upregulation had a poor prognosis. However, a previous study showed that cervical cancer patients (FIGO stage Ib1-IIIb) with low (*n*=2) or high HspB1 (*n*=4) expression levels had poorer prognoses than patients with moderate protein expression levels (*n*=8) ([@bib24]). The different results between these two studies may be due to different sample cohorts and sample quantities (105 samples versus 14 samples).

MnSOD (also called SOD~2~) is localised to the mitochondria and can catalyse the superoxide radical (O~2~^−^) to H~2~O~2~ and hydro-peroxides. H~2~O~2~ and hydro-peroxides then promote oxidative stress, which contributes to tumour progression and metastasis ([@bib35]). MnSOD has attracted the attention of many investigators because of its overexpression in various types of human malignancies such as colorectal ([@bib28]), gastric ([@bib25]), and oral squamous cell carcinomas ([@bib23]), and it is often associated with metastatic progression ([@bib25]; [@bib23]). Additionally, some studies have shown that MnSOD-dependent upregulation of MMPs (including MMP-1 and MMP-9) may contribute to the increased invasive and metastatic capacities of tumours ([@bib27]). In cervical cancer, a correlation of MnSOD upregulation with different stages of cancer was shown ([@bib36]), but there is no report of studying its association with PLNM. Our study showed a significant correlation between MnSOD expression and PLNM (*P*=0.006), which is consistent with previous studies in other tumours ([@bib28]; [@bib23]). Additionally, we found that MnSOD was a significant predictor of PLNM (*P*=0.011) in the univariate analysis. In the multivariate analysis, MnSOD trended towards being an independent predictor of PLNM (*P*=0.053), but the differences did not reach statistical significance. This result may be due to the study\'s relatively small sample size, which affects statistical power. Therefore, our data suggest that MnSOD may be a biomarker for PLNM of CC, I--IIst, and upregulation of MnSOD may support the development of PLNM in CC, I--IIst.

Surgery as a treatment option for CC, I--IIst can offer hope of fertility or function preservation and avoid the damage of ovary and vagina function. Therefore, surgical treatment is a much better option for patients without PLNM and with desire for fertility or function preservation. For patients with PLNM and with desire for function preservation, surgical treatment also can be considered because the normal ovaries can be transposed during the surgery, so that the ovaries will not be damaged by postoperative radiotherapy. For patients with PLNM and without desire for function preservation, chemoradiotherapy should be recommended as the first treatment to avoid the morbidity caused by combining surgery and chemoradiotherapy. In the present study, the combination of FABP5, HspB1, and MnSOD had a good discrimination power (AUC=0.929), high sensitivity and specificity (86.36% and 85.54%, respectively), high NPV (95.7%), and moderate PPV (61.3%) for the identification of CC, I--IIst patients with PLNM. These test characteristics are based on the decision to use 0.2448 (by maximising the Youden index) as a cut-point. Because of the high NPV, these proteins can be helpful in the clinical decision-making process. If a patient has a NPLNM diagnosed by the combination of these proteins (cut-point=0.2448, NPV=95.7%), then the clinician can plan surgery (fertility preservation or function preservation) for patients, which depends on the patient\'s desire. If a patient has a PLNM diagnosed by the combination of these proteins (cut-point=0.654, by maximising PPV to 92.3%), then the clinician can recommend chemoradiotherapy or function preservation surgery (plus postoperative adjuvant therapy) for patients, which depends on the patient\'s desire. As primary cervical cancer tissues can be easily obtained by transvaginal biopsy for detecting the expression levels of these proteins before treatment, these proteins can be applied to evaluate PLNM for CC, I--IIst patients before the first management.

Consistent with previous studies ([@bib30]), our results revealed that LVSI was also an independent predictor of PLNM. When comparing PLNM prediction capacities, we observed that the AUCs of HspB1 (0.803) and FABP5 (0.761) were higher than the AUC of LVSI (0.749). Additionally, when combining FABP5, HspB1, and MnSOD, we found that the discriminatory power was significantly improved ([Figure 4](#fig4){ref-type="fig"}). The AUC of LVSI (0.749) was much lower than that of the combination of the three proteins (0.929). These findings suggest that FABP5, HspB1, and MnSOD may be promising biomarker candidates for identifying CC, I--IIst patients with PLNM.

Previous studies have shown that stromal invasion is an important predictor of PLNM in cervical cancer ([@bib10]; [@bib2]). In our study, univariate analysis showed that stromal invasion was a significant predictor of PLNM (*P*=0.006). However, in multivariate analysis, it was not an independent predictor of PLNM (*P*=0.074). This may be due to the small sample size, which is a main limitation of our study. The reason for the small sample size was that only patients without preoperative adjuvant therapy and with complete follow-up data were eligible to be enrolled in our study. Moreover, the incidence of PLNM in CC, I--IIst is low. Therefore, the sample size of this study was relatively small. Another limitation of the present study is that only one pathological type of cervical cancer (squamous cell cancer) was studied. This was because of the need for homogenous samples in proteomic analysis. On the other hand, the prevalence of other pathological types of cervical cancer is low so that we could not collect enough tumour samples for the study. Thus future studies with larger sample sizes and different pathological types need to be performed.

In summary, we identified 41 differentially expressed proteins between primary CC, I--IIst tissues with and without PLNM using DIGE-based proteomics. We further found that three differentially expressed proteins (FABP5, HspB1, and MnSOD) are potential biomarkers for PLNM of CC, I--IIst, and may contribute to the pathogenesis of PLNM. These findings may help clinicians to design optimal individualised treatment plans before first treatment.
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![**Representative DIGE gel image of differentially expressed proteins in primary early-stage cervical cancer with and without PLNM.** Proteins extracted from the two groups were labelled with Cy3 (green, PLNM) and Cy5 (red, NPLNM). An internal standard (a mixture of PLNM and NPLNM CC, I--IIst samples) was labelled with Cy2 (blue). The yellow arrow indicates the significantly differentially expressed protein points in the PLNM and NPLNM groups. The number in the figure corresponds to the number shown in [Table 2](#tbl2){ref-type="table"}. The full colour version of this figure is available at *British Journal of Cancer* online.](bjc201492f1){#fig1}

![**Validation of FABP5, HspB1, and MnSOD expression in early-stage cervical cancer with and without PLNM, and their discriminatory power as proteomic biomarkers.** (**A**) Representative results of immunohistochemical staining of FABP5, HspB1, and MnSOD in early-stage cervical cancer with and without PLNM. (**B**) Representative results of western blotting of FABP5, HspB1, and MnSOD in early-stage cervical cancer with and without PLNM. GAPDH is used as an internal loading control. (**C**) ROC curves of FABP5, HspB1, MnSOD, and LVSI as markers to differentiate PLNM in early-stage cervical cancer (HspB1 AUC=0.803; MnSOD AUC=0.713; FABP5 AUC=0.761; LVSI AUC=0.749; the combination of FABP5, HspB1, and MnSOD AUC=0.929).](bjc201492f2){#fig2}

![**Kaplan--Meier survival plots for early-stage cervical cancer according to the expression levels of FABP5, HspB1, and MnSOD.** (**A**) FABP5 expression and overall survival (log-rank test, *P*\<0.001). (**B**) FABP5 expression and relapse-free probability (log-rank test, *P*\<0.001). (**C**) HspB1 expression and overall survival (log-rank test, *P*\<0.001). (**D**) HspB1 expression and relapse-free probability (log-rank test, *P*\<0.001). (**E**) MnSOD expression and overall survival (log-rank test, *P*=0.001). (**F**) MnSOD expression and relapse-free probability (log-rank test, *P*=0.001).](bjc201492f3){#fig3}

![**Classification analysis of differentially expressed proteins in early-stage cervical cancer with and without PLNM.** (**A**) Classification of the differential proteins according to biological process. (**B**) Classification of the differential proteins according to molecular function. (**C**) Classification of the differential proteins according to protein class.](bjc201492f4){#fig4}

###### Clinicopathological data of early-stage cervical cancer patients included in the proteomic study

  **No.**                                        **Age (years)**    **FIGO stage**   **Tumour size (cm)**  **Number of positive PLN**   **Number of removed PLN**   **LVSI**    **Differentiation**   **Pathological type**   **Stromal invasion**
  ---------------------------------------------- ----------------- ---------------- ---------------------- ---------------------------- --------------------------- ---------- --------------------- ----------------------- ----------------------
  **Early-stage cervical cancer with PLNM**                                                                                                                                                                                  
  1                                              41                      IIa1                 3            2                            34                          Negative            G2                     Scc                   \>1/2
  2                                              56                      Ib1                 2.5           3                            36                          Negative            G2                     Scc                   \>1/2
  3                                              42                      IIa2                 5            2                            32                          Negative            G3                     Scc                   \>1/2
  4                                              58                      IIa1                3.5           2                            40                          Negative            G3                     Scc                   \<1/2
  5                                              39                      Ib2                  5            1                            47                          Negative            G2                     Scc                   \>1/2
  6                                              58                      Ib1                  3            4                            41                          Negative            G2                     Scc                   \>1/2
  7                                              67                      IIa2                 5            13                           43                          Positive            G2                     Scc                   \>1/2
  8                                              35                      Ib1                 3.5           7                            35                          Negative            G3                     Scc                   \<1/2
  **Early-stage cervical cancer without PLNM**                                                                                                                                                                               
  1                                              40                      IIa2                 5            0                            35                          Negative            G2                     Scc                   \>1/2
  2                                              64                      Ib1                  2            0                            34                          Negative            G2                     Scc                   \<1/2
  3                                              53                      IIa1                3.5           0                            41                          Negative            G2                     Scc                   \<1/2
  4                                              32                      Ib1                  3            0                            37                          Negative            G2                     Scc                   \>1/2
  5                                              42                      Ib2                  5            0                            43                          Negative            G2                     Scc                   \>1/2
  6                                              42                      Ib1                  3            0                            48                          Negative            G3                     Scc                   \<1/2
  7                                              49                      IIa1                3.5           0                            30                          Negative            G2                     Scc                   \>1/2
  8                                              57                      Ib1                  3            0                            51                          Positive            G2                     Scc                   \>1/2
  9                                              48                      IIa2                4.5           0                            46                          Negative            G3                     Scc                   \>1/2
  10                                             52                      IIa1                 3            0                            48                          Negative            G3                     Scc                   \<1/2

Abbreviations: FIGO=the International Federation of Gynaecology and Obstetrics; LVSI=lymphovascular space invasion; PLN=pelvic lymph node; PLNM=pelvic lymph node metastasis Scc=squamous cell carcinoma.

###### Differential proteins between early-stage cervical cancer with and without PLNM identified by MALDI-TOF/TOF MS

  **Master no.**    **Accession no.**  **Mr**    **PI**   **Mascot score**   **Coverage (%)**   **Fold change (PLNM/NPLNM)**   **Protein name**
  ---------------- ------------------- --------- -------- ------------------ ------------------ ------------------------------ -------------------------------------------------------------------------
  117                    P12110        109 709   5.85     96                 14%                2.19                           COL6A2 Isoform 2C2 of Collagen alpha-2(VI) chain
  312                    P02679        50 092    5.7      68                 10%                −4.05                          FGG Isoform Gamma-A of Fibrinogen gamma chain
  343                    Q05707        92 740    4.70     98                 18%                4.67                           COL14A1 93 kDa protein
  353                    P02679        50 092    5.7      124                18%                −6.04                          FGG Isoform Gamma-A of Fibrinogen gamma chain
  357                    P02679        50 092    5.7      77                 10%                −8.02                          FGG Isoform Gamma-A of Fibrinogen gamma chain
  462                    P02787        79 294    6.81     359                46%                1.53                           TF Serotransferrin
  528                    BOYJC5        26 956    4.68     70                 26%                −5.45                          VIM Vimentin variant 4
  627                    Q9UBG3        53 730    5.73     84                 21%                3.68                           CRNN Cornulin
  710                    B4E3Q9        101 217   5.35     86                 15%                −1.52                          VCL cDNA FLJ59659, highly similar to Vinculin
  721                    Q96AX9        82 990    7.41     71                 6%                 −2.49                          MIB2 E3 ubiquitin-protein ligase MIB2 isoform 5
  743                    P02675        56 577    8.54     80                 18%                −3.2                           FGB Fibrinogen beta chain
  834                    B4DRR0        58 088    8.09     210                36%                −3.53                          KRT6A cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A
  844                    P13647        62 568    7.59     335                40%                −2.32                          KRT5 Keratin, type II cytoskeletal 5
  848                    B4DRR0        58 088    8.09     368                47%                −2.86                          KRT6A cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A
  924                    B4DRR0        58 088    8.09     388                53%                −7.89                          KRT6A cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A
  1094                   B4E1D3        50 436    8.22     148                24%                −5.97                          FGB fibrinogen beta chain isoform 2 preproprotein
  1101                   B4E1D3        50 436    8.22     251                43%                −5.66                          FGB fibrinogen beta chain isoform 2 preproprotein
  1228                   B4DW52        38 950    5.19     84                 13%                1.59                           ACTB cDNA FLJ55253, highly similar to Actin, cytoplasmic 1
  1252                   B4E1D3        50 436    8.22     192                39%                −2.02                          FGB fibrinogen beta chain isoform 2 preproprotein
  1437                   P17706        41 363    5.98     69                 10%                2.46                           PTPN2 tyrosine-protein phosphatase non-receptor type 2
  1557                   P67936        28 619    4.67     251                42%                2.16                           TPM4 Isoform 1 of Tropomyosin alpha-4 chain
  1604                   B4E3A4        40 116    5.23     169                21%                −3.84                          cDNA FLJ57283, highly similar to Actin, cytoplasmic 2
  1615                   P02679        50 092    5.7      109                17%                −4.69                          FGG Isoform Gamma-A of Fibrinogen gamma chain
  1625                   P30101        13 739    6.78     131                33%                2.52                           PDIA3 14 kDa protein
  1629                   P04075        39 851    8.3      63                 11%                2.05                           ALDOA Fructose-bisphosphate aldolase A
  1639                   E7EQV7        58 718    6.6      333                28%                −7.69                          KRT6C Uncharacterized protein
  1706                   P14618        58 538    7.6      103                13%                2.89                           PKM2 Isoform M1 of Pyruvate kinase isozymes M1/M2
  1707                   P49761        74 267    9.94     73                 8%                 −4.3                           CLK3 Isoform 4 of Dual specificity protein kinase CLK3
  1757                   P04792        22 826    5.98     305                42%                15.22                          HSPB1 Heat shock protein beta-1
  1758                   P60709        42 052    5.29     197                39%                2.06                           ACTB Actin, cytoplasmic 1
  1801                   P13647        23 267    4.82     343                49%                −3.88                          KRT5 Keratin, type II cytoskeletal 5
  1826                   P02768        23 414    5.93     164                47%                1.6                            ALB 23 kDa protein
  1840                   E7EUE8        56 065    5.95     247                31%                −3.51                          KRT6A Uncharacterized protein
  1879                   P04792        22 826    5.98     238                51%                5.11                           HSPB1 Heat shock protein beta-1
  1899                   B4DRR0        58 088    8.09     251                29%                −2.44                          KRT6A cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A
  1908                   E9PH29        26 107    7.04     74                 14%                2.27                           PRDX3 thioredoxin-dependent peroxide reductase, mitochondrial isoform b
  1947                   P04179        24 878    8.35     169                44%                2.57                           SOD2 Superoxide dismutase \[Mn\], mitochondrial
  1990                   P09211        23 569    5.43     171                43%                2.27                           GSTP1 Glutathione S-transferase P
  2010                   E7EUE8        56 065    5.95     216                23%                −2.57                          KRT6A Uncharacterized protein
  2012                   B4DNH8        2182      5.98     75                 37%                −1.53                          cDNA FLJ59138, highly similar to Annexin A2
  2153                   B4DNG6        18 212    4.99     90                 44%                2.68                           ANXA5 ANXA5 Uncharacterized protein
  2194                   G5E9R0        13 907    5.24     246                54%                1.51                           ACTB 14 kDa protein
  2267                   P25398        14 905    6.81     85                 25%                2.8                            RPS12 40S ribosomal protein S12
  2286                   Q01469        15 497    6.6      84                 57%                7.49                           FABP5 Fatty acid-binding protein, epidermal
  2308                   P20674        16 923    6.3      100                11%                3.46                           COX5A Cytochrome c oxidase subunit 5A, mitochondrial
  2349                   P09382        15 048    5.34     311                62%                1.6                            LGALS1 Galectin-1
  2353                   P06702        13 291    5.71     101                90%                −2.47                          S100A9 Protein S100-A9
  2385                   O94964        185 512   6.15     63                 7%                 2.84                           KIAA0889 Isoform 2 of Uncharacterized protein KIAA0889
  2498                   P31949        11 847    6.56     65                 28%                1.51                           S100A11 Protein S100-A11
  2506                   P05109        10 885    6.51     194                67%                −2.17                          S100A8 Protein S100-A8
  2530                   Q9H628        7191      9.06     64                 48%                1.53                           RERGL 7 kDa protein
  2544                   F8VYY1        7837      9.81     62                 31%                2.6                            CDK4 Uncharacterized protein

Abbreviations: MALDI-TOF/TOF MS=matrix-assisted laser desorption/ionisation--time-of-flight mass spectrometry; Mr=relative molecular mass; NPLNM=no pelvic lymph node metastasis; PI=isoelectric point; PLNM=pelvic lymph node metastasis.

###### Associations of FABP5, HspB1, and MnSOD expression levels with clinicopathological factors in early-stage cervical cancer

                          ***N***   **HspB1**  **MnSOD**               **FABP5**                                                                        
  ---------------------- --------- ----------- ----------- ---------------------------------- ---- ------- ---------------------------------- ---- ---- ------------------------------
  Age (years)               --         --      --                        0.761                --     --                  0.918                --   --               0.121
   ⩽35                      21         14      7                           --                 14      7                    --                 17   4                  --
   \>35                     84         53      31                          --                 55     29                    --                 53   31                 --
  FIGO stage                --         --                                0.205                --     --                  0.745                --   --               0.076
   Ia2                      12          9      3                           --                 10      2                    --                 12   0                  --
   Ib1                      37         28      9                           --                 24     13                    --                 24   13                 --
   Ib2                      22         13      9                           --                 14      8                    --                 15   7                  --
   IIa1                     16          8      8                           --                 10      6                    --                 10   6                  --
   IIa2                     18          9      9                           --                 11      7                    --                 9    9                  --
  Tumour size (cm)          --         --      --                        0.059                --     --                  0.586                --   --               0.256
   ⩽4                       65         46      19                          --                 44     21                    --                 46   19                 --
   \>4                      40         21      19                          --                 25     15                    --                 24   16                 --
  PLNM                      --         --      --                       \<0.001               --     --                 \< 0.001              --   --              \<0.001
   Positive                 22          7      15                          --                 10     12                    --                 6    16                 --
   Negative                 83         60      23                          --                 58     25                    --                 64   19                 --
  LVSI                      --         --      --                        0.287                --     --                   0.01                --   --               0.001
   Positive                 16          8      8                           --                 6      10                    --                 5    11                 --
   Negative                 89         59      30                          --                 63     26                    --                 65   24                 --
  Differentiation           --         --      --           0.366[a](#t3-fn2){ref-type="fn"}  --     --     0.555[a](#t3-fn2){ref-type="fn"}  --   --    1[a](#t3-fn2){ref-type="fn"}
   G1                        6          4      2                           --                 3       3                    --                 4    2                  --
   G2                       37         27      10                          --                 26     11                    --                 25   12                 --
   G3                       62         36      26                          --                 40     22                    --                 41   21                 --
  Stomal invasion           --         --      --                          --                 --    0.002                  --                 --   --               0.096
   ⩽1/2                     48         35      13                          --                 39      9                    --                 36   12                 --
   \>1/2                    57         32      25                          --                 29     28                    --                 34   23                  
  Parametrial invasion      --         --      --                          1                  --     --                    1                  --   --               0.064
   Positive                  9          6      3                           --                 6       3                    --                 3    6                  --
   Negative                 96         61      35                          --                 63     33                    --                 67   29                 --
  Vaginal invasion          --         --      --                        0.948                --     --                  0.184                --   --                0.37
   Positive                 19         12      7                           --                 10      9                    --                 11   8                  --
   Negative                 86         55      31                          --                 59     27                    --                 59   27                 --

Abbreviations: FIGO=the International Federation of Gynecology and Obstetrics; LVSI=lymphovascular space invasion; PLNM=pelvic lymph node metastasis.

*P* value from Fisher\'s exact test.

###### Univariate and multivariate logistic regression analyses of factors associated with pelvic LN metastasis

  **Variables**                                                   **HR (95% CI)**          ***P*-value**
  --------------------------------------------------------------- ------------------------ ---------------
  **Univariate analysis,** ***n***=**105**                                                 
  Age (years)                                                     0.976 (0.919--1.037)     0.428
  Tumour size (cm)                                                1.768 (1.219--2.564)     0.003
  Differentiation                                                                          0.963
   G1 (reference)                                                 1                         
   G2                                                             1.379 (0.140--13.556)    0.783
   G3                                                             1.327 (0.142--12.366)    0.804
  FIGO stage                                                                               0.116
   I (reference)                                                  1                         
   II                                                             2.174 (0.826--5.718)      
  LVSI                                                                                     \< 0.001
   Negative (reference)                                           1                         
   Positive                                                       23.700 (6.402--87.741)    
  Stromal invasion                                                                         0.006
   ⩽1/2 (reference)                                               1                         
   \>1/2                                                          5.077 (1.582--16.293)     
  Parametrial invasion                                                                     0.348
   Negative (reference)                                           1                         
   Positive                                                       2.026 (0.464--8.849)      
  Vaginal invasion                                                                         0.214
   Negative (reference)                                           1                         
   Positive                                                       2.019 (0.666--6.123)      
  MnSOD                                                                                    0.011
   Low (reference)                                                1                         
   High                                                           3.551 (1.342--9.399)      
  HspB1                                                                                    0.001
   Low (reference)                                                1                         
   High                                                           5.59 (2.020--15.468)      
  FABP5                                                                                    \< 0.001
   Low (reference)                                                1                         
   High                                                           6.750 (2.413--18.880)     
  **Multivariate analysis[a](#t4-fn2){ref-type="fn"}, *n*=105**                            
  LVSI                                                                                     0.001
   Negative (reference)                                           1                         
   Positive                                                       17.512 (3.181--96.420)    
  Stromal invasion                                                                         0.074
   ⩽1/2 (reference)                                               1                         
   \>1/2                                                          4.038 (0.872--18.701)     
  HspB1                                                                                    0.013
   Low (reference)                                                1                         
   High                                                           6.379 (1.480--27.482)     
  FABP5                                                                                    0.018
   Low (reference)                                                1                         
   High                                                           5.829 (1.355-25.075)      
  MnSOD                                                                                    0.053
   Low (reference)                                                1                         
   High                                                           4.053 (0.980--16.769)     

Abbreviations: 95% CI=95% confidence interval; FIGO=the International Federation of Gynaecology and Obstetrics; HR=hazard ratio; LVSI=lymphovascular space invasion.

For the stepwise multivariate analysis, backward LR method was used to drop insignificant variables. Variables entered for analysis were the following: age, tumour size, differentiation, FIGO stage, LVSI, stomal invasion, parametrial invasion, vaginal invasion, FABP5, HspB1, and MnSOD.

###### Sensitivity, specificity, AUC, positive-, and negative-predictive values of factors associated with pelvic LN metastasis

  **Factors**         **Sensitivity (95% CI) (%)**   **Specificiy (95% CI) (%)**   **PPV (95% CI) (%)**   **NPV (95% CI) (%)**   **AUC (95% CI)**
  ------------------- ------------------------------ ----------------------------- ---------------------- ---------------------- ----------------------
  HspB1               54.55 (32.2--75.6)             95.18 (88.1--98.7)            75 (47.6--92.7)        88.8 (80.3--94.5)      0.803 (0.714--0.874)
  FABP5               68.18 (45.1--86.1)             75.9 (65.3--84.6)             42.9 (26.3--60.6)      90 (80.5--95.9)        0.761 (0.668--0.839)
  MnSOD               63.64 (40.7--82.8)             74.7 (64.0--83.6)             40 (23.9--57.9)        88.6 (78.7--94.9)      0.713 (0.616--0.797)
  HspB1+FABP5+MnSOD   86.36 (65.1--97.1)             85.54 (76.1--92.3)            61.3 (42.2--78.2)      95.9 (88.5--99.2)      0.929 (0.862--0.970)

Abbreviations: 95% CI=95% confidence interval; AUC=the area under the receiver operating characteristic curve; NPV=negative predictive value; PPV=positive predictive value.
